Home » Stocks » BDSX

Biodesix, Inc. (BDSX)

Stock Price: $27.17 USD -0.42 (-1.52%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $25.00 -2.17 (-7.99%) Jan 25, 4:45 PM
Market Cap 704.67M
Revenue (ttm) 21.55M
Net Income (ttm) -34.10M
Shares Out 26.25M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $27.17
Previous Close $27.59
Change ($) -0.42
Change (%) -1.52%
Day's Open 27.53
Day's Range 25.18 - 28.84
Day's Volume 144,015
52-Week Range 10.89 - 31.21


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse ...

PRNewsWire - 1 week ago

NEW YORK and BOULDER, Colo., Jan. 13, 2021 /PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with...

Seeking Alpha - 2 months ago

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...

Other stocks mentioned: ALGM, AVIR, GATO, GLTO, LESL, LU, MAX, ROOT, SQZ
Seeking Alpha - 2 months ago

Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.

About BDSX

Biodesix operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutica... [Read more...]

Diagnostics & Research
IPO Date
Oct 28, 2020
Scott Hutton
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Biodesix's revenue was $24.55 million, an increase of 20.16% compared to the previous year's $20.43 million. Losses were -$30.73 million, 17.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Biodesix stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is a decrease of -15.35% from the latest price.

Price Target
(-15.35% downside)
Analyst Consensus: Strong Buy